Cancer Family
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
CI-CAN-00000175Explore in graph →
Non-malignant81 active trials1 approved drugs18 evidence items
- NCIt
- C27291
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000175Explore in graph →
Clinical trials
253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04661852 | Cabozantinib With Topotecan-Cyclophosphamide | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04956198 |
| Drug Sensitivity and Mutation Profiling |
| completed |
| — |
| 14 |
| Florida International UniversityOTHER |
| 1 |
| Feb 14, 2023 |
| clinicaltrials |
| NCT02511132 | A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma | completed | Phase 2 | 22 | Gradalis, Inc.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT03359005 | Irinotecan and Temozolomide for Ewing Sarcoma | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02063022 | Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma(EW-1) | completed | Phase 3 | 278 | Italian Sarcoma GroupNETWORK | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02727387 | Protocol for the Treatment of Metastatic Ewing Sarcoma(EW-2) | completed | Phase 2 | 155 | Italian Sarcoma GroupNETWORK | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT03275818 | Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma(ABRADES) | completed | Phase 2 | 69 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | unknown | Phase 1 | 30 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01061840 | Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer | completed | Phase 1 | 100 | Gradalis, Inc.INDUSTRY | 1 | Mar 15, 2022 | clinicaltrials |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | completed | Phase 1 | 25 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT02044120 | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | completed | Phase 1 | 34 | Sarcoma Alliance for Research through CollaborationOTHER | 2 | Jan 12, 2021 | clinicaltrials |
| NCT02520128 | A Study of IMRT in Primary Bone and Soft Tissue Sarcoma(IMRiS) | completed | N/A | 191 | University College, LondonOTHER | 2 | Dec 2, 2020 | clinicaltrials |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02159443 | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | completed | — | 76 | St. Jude Children's Research HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT00026780 | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | completed | — | 1,720 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2020 | clinicaltrials |
| NCT00001686 | Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases | completed | — | 482 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00038142 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | terminated | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03968471 | Chemotherapy-induced Necrosis in Ewing Sarcoma | completed | — | 474 | Istituto Ortopedico RizzoliOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT00339898 | Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma | completed | — | 414 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00001564 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00004853 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00987636 | Study in Localized and Disseminated Ewing Sarcoma(EWING2008) | completed | Phase 3 | 907 | University Hospital MuensterOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02546544 | Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma(LINES) | completed | Phase 2 | 16 | University of OxfordOTHER | 5 | Jun 3, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03029481 | Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Mar 28, 2019 | clinicaltrials |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03416517 | Anlotinib and Irinotecan for Ewing Sarcoma | unknown | Phase 1 / Phase 2 | 47 | Peking University People's HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00070109 | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | completed | Phase 2 | 50 | Children's Oncology GroupNETWORK | 2 | Sep 14, 2018 | clinicaltrials |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | terminated | Phase 2 | 219 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Feb 21, 2023source: clinicaltrials